Participants with the variants did not respond differently to other common diabetes treatments, including sulfonylureas, metformin and DPP-4i
If a patient comes in who weighs 500 pounds, and we never say anything other than, Oh yeah, just eat less, exercise more
Studies show that adding lifestyle changes to GLP-1 treatment can reduce cardiovascular risk by up to 43 percent
Moreover, we offer flexibility in designing weight loss drug coverage to meet the specific needs of our plan sponsors
FDAs Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
GLP-1 agonist drug sales increased 58.2% between December 2022 and December 2023, with Ozempic and Mounjaro driving most of that growth volume